PA
Profund Advisors Portfolio holdings
AUM
$2.78B
1-Year Return
29.53%
This Quarter Return
+15.99%
1 Year Return
+29.53%
3 Year Return
+153.44%
5 Year Return
+262.59%
10 Year Return
+738.89%
AUM
$2.57B
AUM Growth
+$240M
(+10%)
Cap. Flow
+$2.26M
Cap. Flow
% of AUM
0.09%
Top 10 Holdings %
Top 10 Hldgs %
34.11%
Holding
1,211
New
84
Increased
525
Reduced
539
Closed
63
Top Buys
| 1 |
NVIDIA
NVDA
|
$23.5M |
| 2 |
Linde
LIN
|
$16.4M |
| 3 |
Broadcom
AVGO
|
$3.16M |
| 4 |
Advanced Micro Devices
AMD
|
$2.67M |
| 5 |
Qualcomm
QCOM
|
$1.54M |
Top Sells
| 1 |
Exxon Mobil
XOM
|
$6.7M |
| 2 |
Microsoft
MSFT
|
$5.59M |
| 3 |
Chevron
CVX
|
$4.56M |
| 4 |
Meta Platforms (Facebook)
META
|
$4.45M |
| 5 |
Viking Therapeutics
VKTX
|
$3.77M |
Sector Composition
| 1 | Technology | 42.5% |
| 2 | Healthcare | 12.67% |
| 3 | Consumer Discretionary | 11.07% |
| 4 | Communication Services | 9.14% |
| 5 | Financials | 5.28% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
276
PG&E
PCG
$33.2B
| $1.33M | 0.05% |
79,622
-6,625
| -8% | -$111K |
|
277
Intellia Therapeutics
NTLA
$1.29B
| $1.33M | 0.05% |
48,300
-2,676
| -5% | -$73.6K |
|
278
Apellis Pharmaceuticals
APLS
$3.55B
| $1.32M | 0.05% |
22,533
-25
| -0.1% | -$1.47K |
|
279
Kymera Therapeutics
KYMR
$3.11B
| $1.32M | 0.05% |
32,825
+12,938
| +65% | +$520K |
|
280
ZTO Express
ZTO
$14.7B
| $1.32M | 0.05% |
62,936
-4,794
| -7% | -$100K |
|
281
Enphase Energy
ENPH
$5.18B
| $1.32M | 0.05% |
10,876
+1,518
| +16% | +$184K |
|
282
Twist Bioscience
TWST
$1.55B
| $1.31M | 0.05% |
38,230
+616
| +2% | +$21.1K |
|
283
Petrobras Class A
PBR.A
$72.8B
| $1.31M | 0.05% |
87,748
-15,278
| -15% | -$228K |
|
284
TG Therapeutics
TGTX
$5.11B
| $1.3M | 0.05% |
85,796
-7,693
| -8% | -$117K |
|
285
Dow Inc
DOW
$17.4B
| $1.3M | 0.05% |
22,517
-1,456
| -6% | -$84.3K |
|
286
Hilton Worldwide
HLT
$64B
| $1.29M | 0.05% |
6,067
+605
| +11% | +$129K |
|
287
Nucor
NUE
$33.8B
| $1.29M | 0.05% |
6,530
+79
| +1% | +$15.6K |
|
288
AutoZone
AZO
$70.6B
| $1.29M | 0.05% |
410
+25
| +6% | +$78.8K |
|
289
Entegris
ENTG
$12.4B
| $1.28M | 0.05% |
9,134
+1,970
| +27% | +$277K |
|
290
Ultragenyx Pharmaceutical
RARE
$3.07B
| $1.28M | 0.05% |
27,484
-7,531
| -22% | -$352K |
|
291
Itaú Unibanco
ITUB
$76.6B
| $1.28M | 0.05% |
203,641
-35,461
| -15% | -$223K |
|
292
Waste Management
WM
$88.6B
| $1.28M | 0.05% |
6,007
+1,120
| +23% | +$239K |
|
293
Nuvalent
NUVL
$5.83B
| $1.28M | 0.05% |
17,039
-3,656
| -18% | -$275K |
|
294
Catalyst Pharmaceutical
CPRX
$2.48B
| $1.28M | 0.05% |
80,142
+18,578
| +30% | +$296K |
|
295
Beam Therapeutics
BEAM
$2.11B
| $1.28M | 0.05% |
38,636
-16,730
| -30% | -$553K |
|
296
Celldex Therapeutics
CLDX
$1.52B
| $1.27M | 0.05% |
30,347
+5,861
| +24% | +$246K |
|
297
Snap
SNAP
$12.4B
| $1.27M | 0.05% |
110,698
+24,200
| +28% | +$278K |
|
298
Recursion Pharmaceuticals
RXRX
$2.01B
| $1.27M | 0.05% |
127,156
-35,469
| -22% | -$354K |
|
299
Arcutis Biotherapeutics
ARQT
$2.06B
| $1.25M | 0.05% |
+126,283
| New | +$1.25M |
|
300
Geron
GERN
$893M
| $1.24M | 0.05% |
376,360
+100,537
| +36% | +$332K |
|